Skip to main content

Table 3 Incremental cost-effectiveness ratios (ICERs)

From: Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: a cost-effectiveness study

Increment

ICER (£/QALY)

Net benefit in £M

95 % credibility interval

Elderly- and risk-group → 2–4 y

2,613

74

(12–265.7)

2–4 y → 5–16 y

1,569

384.4

(85.4–1309.6)

5–16 y → 2–16 y

3,414

58.7

(8.4–212.8)

2–16 y → 2–16 y & 50–64 y

8,093

75.9

(–11.5 to 346.1)

2–16 y & 50–64 y → 2–64 y

8,868

198.8

(–46.8 to 950.8)

  1. Table of the incremental cost-effectiveness ratios and net benefit for the proposed immunization strategies. Strategies are ordered in terms of their net cost, and the incremental costs and incremental benefits of the next most expensive strategy is compared with the previous one. Dominated strategies (50–64 year age group and 2–4 and 50–64 year age groups) have been excluded
  2. QALY, Quality-adjusted life year
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us